Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape
Therapeutic Advances in Endocrinology and Metabolism · 2026-08 · 19
DOI: 10.1177/20420188261484779 ↗Kurz gefasst
Leserbrief in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 24.08.2026. Verfasst von Hussein Zaitoon. Beteiligte Einrichtung: Division of Pediatric Endocrinology and Diabetes, University of Texas Health Science Center, San Antonio, TX, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Pediatric Endocrinology and Diabetes, University of Texas Health Science Center, San Antonio, TX, USA.
ORCID-Profile: Hussein Zaitoon
Zitieren
APA
Zaitoon, H. (2026). Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape. Therapeutic Advances in Endocrinology and Metabolism, 19. https://doi.org/10.1177/20420188261484779
Vancouver
Zaitoon H. Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape. Therapeutic Advances in Endocrinology and Metabolism. 2026;19. doi:10.1177/20420188261484779
BibTeX
@article{Zaitoon2026,
author = {Zaitoon, Hussein},
title = {Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape},
journal = {Therapeutic Advances in Endocrinology and Metabolism},
year = {2026},
volume = {19},
doi = {10.1177/20420188261484779}
}
EUVIMED